中华器官移植杂志
中華器官移植雜誌
중화기관이식잡지
CHINESE JOURNAL OF ORGAN TRANSPLANTATION
2012年
11期
694-698
,共5页
朱希山%施薇%台卫平%任军
硃希山%施薇%檯衛平%任軍
주희산%시미%태위평%임군
人%脂肪组织%骨髓%间质干细胞
人%脂肪組織%骨髓%間質榦細胞
인%지방조직%골수%간질간세포
Persons%Adipose tissue%Bone marrow%Mesenchymal stem cells
目的 比较脂肪来源间充质干细胞(ADAS)和骨髓来源间充质干细胞(BMSC)的生物学特性.方法 分离ADAS和BMSC,比较它们的表型、细胞倍增时间及分泌的相关因子,分别检测它们对T淋巴细胞的活化、细胞周期、增殖及凋亡的作用.结果 BMSC和ADAS在细胞表型上类似,只有CD106的表达有差异;在增殖速率上,ADAS群体倍增时间为28 h,显著高于BMSC的39 h(P<0.05);ADAS和BMSC同样具有抑制T淋巴细胞增殖的能力,在有丝分裂原刺激和混合淋巴细胞反应的T淋巴细胞增殖中,这种抑制作用都具有剂量依赖性,在1:2时抑制作用极强,但是在1:100时这种抑制作用基本消失;在共培养时,ADAS和BMSC都可以使绝大多数的T淋巴细胞被抑制在G0/G1期,同时也可以抑制T淋巴细胞的早期活化,但是ADAS的上述作用均比BMSC弱;ADAS并不具有抑制T淋巴细胞凋亡的作用,而在TH0细胞向TH 1细胞或TH2细胞分化中所起的作用基本相似,主要抑制TH0细胞向TH1细胞(表达IL-2和IFN-γ的T淋巴细胞)的分化,而对向TH2细胞(表达IL4和IL-10的T淋巴细胞)分化没有明显的影响.结论 ADAS与BMSC具有类似的免疫调节作用,在相同体积的脂肪组织中能够得到的干细胞前体细胞的数量是骨髓组织的10倍以上,因此ADAS较难以获得的BMSC更有广泛的应用前景.
目的 比較脂肪來源間充質榦細胞(ADAS)和骨髓來源間充質榦細胞(BMSC)的生物學特性.方法 分離ADAS和BMSC,比較它們的錶型、細胞倍增時間及分泌的相關因子,分彆檢測它們對T淋巴細胞的活化、細胞週期、增殖及凋亡的作用.結果 BMSC和ADAS在細胞錶型上類似,隻有CD106的錶達有差異;在增殖速率上,ADAS群體倍增時間為28 h,顯著高于BMSC的39 h(P<0.05);ADAS和BMSC同樣具有抑製T淋巴細胞增殖的能力,在有絲分裂原刺激和混閤淋巴細胞反應的T淋巴細胞增殖中,這種抑製作用都具有劑量依賴性,在1:2時抑製作用極彊,但是在1:100時這種抑製作用基本消失;在共培養時,ADAS和BMSC都可以使絕大多數的T淋巴細胞被抑製在G0/G1期,同時也可以抑製T淋巴細胞的早期活化,但是ADAS的上述作用均比BMSC弱;ADAS併不具有抑製T淋巴細胞凋亡的作用,而在TH0細胞嚮TH 1細胞或TH2細胞分化中所起的作用基本相似,主要抑製TH0細胞嚮TH1細胞(錶達IL-2和IFN-γ的T淋巴細胞)的分化,而對嚮TH2細胞(錶達IL4和IL-10的T淋巴細胞)分化沒有明顯的影響.結論 ADAS與BMSC具有類似的免疫調節作用,在相同體積的脂肪組織中能夠得到的榦細胞前體細胞的數量是骨髓組織的10倍以上,因此ADAS較難以穫得的BMSC更有廣汎的應用前景.
목적 비교지방래원간충질간세포(ADAS)화골수래원간충질간세포(BMSC)적생물학특성.방법 분리ADAS화BMSC,비교타문적표형、세포배증시간급분비적상관인자,분별검측타문대T림파세포적활화、세포주기、증식급조망적작용.결과 BMSC화ADAS재세포표형상유사,지유CD106적표체유차이;재증식속솔상,ADAS군체배증시간위28 h,현저고우BMSC적39 h(P<0.05);ADAS화BMSC동양구유억제T림파세포증식적능력,재유사분렬원자격화혼합림파세포반응적T림파세포증식중,저충억제작용도구유제량의뢰성,재1:2시억제작용겁강,단시재1:100시저충억제작용기본소실;재공배양시,ADAS화BMSC도가이사절대다수적T림파세포피억제재G0/G1기,동시야가이억제T림파세포적조기활화,단시ADAS적상술작용균비BMSC약;ADAS병불구유억제T림파세포조망적작용,이재TH0세포향TH 1세포혹TH2세포분화중소기적작용기본상사,주요억제TH0세포향TH1세포(표체IL-2화IFN-γ적T림파세포)적분화,이대향TH2세포(표체IL4화IL-10적T림파세포)분화몰유명현적영향.결론 ADAS여BMSC구유유사적면역조절작용,재상동체적적지방조직중능구득도적간세포전체세포적수량시골수조직적10배이상,인차ADAS교난이획득적BMSC경유엄범적응용전경.
Objective To compare the biological characteristics of adipose-derived mesenchymal stem cells (ADAS) and bone marrow derived mesenchymal stem cells (BMSCs).Methods The adipose and bone marrow-derived sources of mesenchymal stem cells were separated,and their phenotype,cell doubling time and the secretion of factors were compared.They were also used to detect T-cell cycle,activation,and proliferation inhibition.Results BMSCs and ADAS were similar on the cell phenotype and the differences only existed in the expression of only CD106.For the proliferation rate,ADAS grew faster than BMSCs (doubling time 28 h vs.39 h,P<0.05); ADAS and BMSCs also had the same ability to inhibit T cell proliferation,and dose-dependent effects existed in mitogen-stimulated Tcell proliferation and MLR: there was a strong inhibitory effect in 1:2,but this effect disappeared at 1: 100.Both ADAS and BMSCs could arrest most T cells in the G0/G1 phase,but the role of ADAS was weaker than that of the BMSCs.ADAS could not inhibit apoptosis of T cells.ADAS and BMSCs played the same roles in inhibiting the differentiation of TH0 to TH1 or TH2: mainly inhibiting differentiation of TH 0 to TH1 cells (IL-2-and IFN-γ-producing cells),but having no significant effect on TH2 cells (IL-4-and IL 10-producing cells).Conclusion ADAS and BMSC have a similar role in immune regulation.In the same volume,fat tissue has the number of more than 10 times of stem cell precursor cells than that of bone marrow,so adipose tissue is a more promising stem cells transplant source.